文献类型：期刊文献

英文题名：Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications

作者：Zhang, Senbing[1,2];Pu, Yanzhu[1];Liu, Jianning[1];Li, Lewen[1];An, Chibing[2];Wu, Yumin[1];Zhang, Wenjie[1];Zhang, Wenxia[1];Qu, Song[1];Yan, Wenjun[3]

第一作者：Zhang, Senbing

通信作者：Yan, WJ[1]

机构：[1]Gansu Univ Chinese Med, Clin Med Coll 1, Lanzhou, Peoples R China;[2]Hubei Univ Sci & Technol, Affiliated Hosp 1, Xianning Cent Hosp, Dept Anesthesiol, Xianning, Hubei, Peoples R China;[3]Gansu Prov Hosp, Dept Anesthesiol, Lanzhou, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Anesthesiol, Lanzhou, Gansu, Peoples R China.

年份：2024

卷号：15

外文期刊名：FRONTIERS IN PHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-85191330623);WOS:【SCI-EXPANDED(收录号:WOS:001207509700001)】；

基金：The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Natural Science Foundation of China (81860233), Gansu Provincial Clinical Medical Research Center of Anesthesia and Brain Function (21JR7RA675), Gansu Provincial Natural Science Foundation (21JR7RA621), Gansu Provincial Key Research and Development Program Project (23YFFA0046), and the hospital-level project of Xianning Central Hospital / The First Affiliated Hospital of Hubei University of Science and Technology (2022XYB032).

语种：英文

外文关键词：(R)-ketamine; antidepressant efficacy; treatment-resistant depression (TRD); side effects; ischemic stroke; cognitive disorders

摘要：(R, S)- and (S)-ketamine have made significant progress in the treatment of treatment-resistant depression (TRD) and have become a research focus in recent years. However, they both have risks of psychomimetic effects, dissociative effects, and abuse liability, which limit their clinical use. Recent preclinical and clinical studies have shown that (R)-ketamine has a more efficient and lasting antidepressant effect with fewer side effects compared to (R, S)- and (S)-ketamine. However, a recent small-sample randomized controlled trial found that although (R)-ketamine has a lower incidence of adverse reactions in adult TRD treatment, its antidepressant efficacy is not superior to the placebo group, indicating its antidepressant advantage still needs further verification and clarification. Moreover, an increasing body of research suggests that (R)-ketamine might also have significant applications in the prevention and treatment of medical fields or diseases such as cognitive disorders, perioperative anesthesia, ischemic stroke, Parkinson's disease, multiple sclerosis, osteoporosis, substance use disorders, inflammatory diseases, COVID-19, and organophosphate poisoning. This article briefly reviews the mechanism of action and research on antidepressants related to (R)-ketamine, fully revealing its application potential and development prospects, and providing some references and assistance for subsequent expanded research.